AUPH — Aurinia Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $2.09bn
- $1.85bn
- $235.13m
- 91
- 32
- 96
- 86
Annual cashflow statement for Aurinia Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -103 | -181 | -108 | -78 | 5.75 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 26.9 | 42.1 | 32.8 | 38.5 | 13.7 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.52 | -21.6 | -6.82 | -5.61 | 5.45 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -69.9 | -158 | -79.5 | -33.5 | 44.4 |
| Capital Expenditures | -7.34 | -1.5 | -0.292 | -0.718 | -0.281 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -151 | -102 | -60.3 | -5.99 | 39.5 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -158 | -104 | -60.6 | -6.71 | 39.3 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 194 | 221 | 2.43 | -5.13 | -49.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -33.7 | -40.5 | -138 | -45.3 | 34.6 |